A Role for GLP-1 in Treating Hyperphagia and Obesity
- PMID: 32516384
- PMCID: PMC7899438
- DOI: 10.1210/endocr/bqaa093
A Role for GLP-1 in Treating Hyperphagia and Obesity
Abstract
Obesity is a chronic recurring disease whose prevalence has almost tripled over the past 40 years. In individuals with obesity, there is significant increased risk of morbidity and mortality, along with decreased quality of life. Increased obesity prevalence results, at least partly, from the increased global food supply that provides ubiquitous access to tasty, energy-dense foods. These hedonic foods and the nonfood cues that through association become reward predictive cues activate brain appetitive control circuits that drive hyperphagia and weight gain by enhancing food-seeking, motivation, and reward. Behavioral therapy (diet and lifestyle modifications) is the recommended initial treatment for obesity, yet it often fails to achieve meaningful weight loss. Furthermore, those who lose weight regain it over time through biological regulation. The need to effectively treat the pathophysiology of obesity thus centers on biologically based approaches such as bariatric surgery and more recently developed drug therapies. This review highlights neurobiological aspects relevant to obesity causation and treatment by emphasizing the common aspects of the feeding-inhibitory effects of multiple signals. We focus on glucagon like peptide-1 receptor (GLP-1R) signaling as a promising obesity treatment target by discussing the activation of intestinal- and brain-derived GLP-1 and GLP-1R expressing central nervous system circuits resulting from normal eating, bariatric surgery, and GLP-1R agonist drug therapy. Given the increased availability of energy-dense foods and frequent encounters with cues that drive hyperphagia, this review also describes how bariatric surgery and GLP-1R agonist therapies influence food reward and the motivational drive to overeat.
Keywords: GIP; PYY3-36; anatomically distributed neural control of food intake; appetitive behavior; endogenous controls of food intake inhibition; hedonic energy dense foods; increased food supply; nucleus tractus solitarius; reward predictive cues; satiation signals; striatum; vagal afferent transmission; visceral malaise.
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Comment in
-
Hope in Hopeless Times: Gearing Up to Fight the Obesity Pandemic.Endocrinology. 2020 Oct 1;161(10):bqaa144. doi: 10.1210/endocr/bqaa144. Endocrinology. 2020. PMID: 32894767 No abstract available.
Similar articles
-
Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling.Endocrinology. 2009 Jun;150(6):2654-9. doi: 10.1210/en.2008-1479. Epub 2009 Mar 5. Endocrinology. 2009. PMID: 19264875 Free PMC article.
-
Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding.Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R465-70. doi: 10.1152/ajpregu.00179.2014. Epub 2014 Jun 18. Am J Physiol Regul Integr Comp Physiol. 2014. PMID: 24944243 Free PMC article.
-
Paraventricular Thalamic Control of Food Intake and Reward: Role of Glucagon-Like Peptide-1 Receptor Signaling.Neuropsychopharmacology. 2017 Nov;42(12):2387-2397. doi: 10.1038/npp.2017.150. Epub 2017 Jul 19. Neuropsychopharmacology. 2017. PMID: 28811669 Free PMC article.
-
Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms.Peptides. 2020 Sep;131:170342. doi: 10.1016/j.peptides.2020.170342. Epub 2020 Jun 6. Peptides. 2020. PMID: 32522585 Review.
-
The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake.Int J Obes (Lond). 2009 Apr;33 Suppl 1:S11-5. doi: 10.1038/ijo.2009.10. Int J Obes (Lond). 2009. PMID: 19363500 Review.
Cited by
-
The Expanding Role of GLP-1: From Diabetes Management to Cancer Treatment.Clin Med Insights Endocrinol Diabetes. 2023 Nov 10;16:11795514231213566. doi: 10.1177/11795514231213566. eCollection 2023. Clin Med Insights Endocrinol Diabetes. 2023. PMID: 38023734 Free PMC article. No abstract available.
-
Protein intake and body weight, fat mass and waist circumference: an umbrella review of systematic reviews for the evidence-based guideline on protein intake of the German Nutrition Society.Eur J Nutr. 2024 Feb;63(1):3-32. doi: 10.1007/s00394-023-03220-x. Epub 2023 Oct 4. Eur J Nutr. 2024. PMID: 37794213 Free PMC article. Review.
-
Food reinforcement architecture: A framework for impulsive and compulsive overeating and food abuse.Obesity (Silver Spring). 2023 Jul;31(7):1734-1744. doi: 10.1002/oby.23792. Obesity (Silver Spring). 2023. PMID: 37368515 Review.
-
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. eCollection 2023. Front Immunol. 2023. PMID: 37266425 Free PMC article. Review.
-
A potentially serious adverse effect of GLP-1 receptor agonists.Acta Pharm Sin B. 2023 May;13(5):2291-2293. doi: 10.1016/j.apsb.2023.02.020. Epub 2023 Mar 2. Acta Pharm Sin B. 2023. PMID: 37250165 Free PMC article. No abstract available.
References
-
- Ogden CL, Carroll MD.. Prevalence of overweight, obesity, and extreme obesity among adults: United States, Trends 1960–1962 Through 2007–2008, in Division of Health and Nutrition Examination Surveys; CDCs National Center for Health Statistics; 2010:1-6.
-
- Hales CM, et al. . Prevalence of obesity and severe obesity among adults: United States 2017–2018, in NCHS Data Brief, no 360; 2020. - PubMed
-
- Bray GA, Kim KK, Wilding JPH; World Obesity Federation Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. - PubMed
-
- Ward ZJ, Bleich SN, Cradock AL, et al. . Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
